DNAJC5 and parasitic infectious disease: Prespecified secondary endpoints were (1) immunology (specifically antibody responses to CSP measured by enzyme-linked immunosorbent assay (ELISA) and T cell responses to ME-TRAP peptides measured by ELISPOT) and (2) efficacy (time to parasitemia >20, >500, >1,000 and >10,000, respectively).